Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia

Leukemia. 2015 May;29(5):1206-9. doi: 10.1038/leu.2014.342. Epub 2014 Dec 8.

Authors

D Rea¹, T Mirault², E Raffoux¹, N Boissel³, A L Andreoli⁴, P Rousselot⁵, H Dombret¹, E Messas²

Affiliations

¹ Hématologie Adulte, Hôpital Saint-Louis, AP-HP, Paris, France.
² 1] Médecine vasculaire, Hôpital européen Georges Pompidou, AP-HP, Paris, France [2] INSERM UMR970, PARCC, Paris Descartes University, Sorbonne Paris Cité, Paris, France.
³ Hématologie Adolescents et Jeunes Adultes, Hôpital Saint-Louis, AP-HP, Paris, France.
⁴ Centre d'Investigation Clinique, Hôpital Saint-Louis, AP-HP, Paris, France.
⁵ Hématologie et Oncologie, Hôpital André Mignot, Université de Versailles, Le Chesnay, France.

PMID: 25482133
DOI: 10.1038/leu.2014.342

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Algorithms
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Cardiovascular Diseases / complications*
Cardiovascular Diseases / diagnosis
Clinical Trials, Phase III as Topic
DNA Mutational Analysis
Disease-Free Survival
Europe
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Middle Aged
Pyrimidines / adverse effects
Pyrimidines / therapeutic use*
Randomized Controlled Trials as Topic
Retrospective Studies
Risk Assessment / methods*
Risk Factors
Treatment Outcome
Young Adult

Substances

Antineoplastic Agents
Pyrimidines
nilotinib